TELA Bio, Inc. - TELA STOCK NEWS

TELA Bio, Inc. (NASDAQ: TELA), a leading medical technology company, has announced that it will release its first quarter 2023 financial results on May 11, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in innovative soft-tissue reconstruction solutions, aiming to enhance clinical outcomes while preserving the patient's anatomy. Interested investors can register to listen to the call online, with options for a replay available post-event. The company emphasizes its commitment to advanced, economically effective solutions that leverage patients' natural healing responses.

TELA Bio, Inc. announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at $9.50 per share, aiming for gross proceeds of $45.125 million. This offering will close on April 21, 2023, subject to customary closing conditions. Additionally, underwriters received a 30-day option for 712,500 additional shares. The funds will be utilized for general corporate purposes, including sales and marketing, research and development, and working capital. The offering is made under an effective shelf registration statement.

TELA Bio, Inc. has announced a public offering of its common stock, with underwriters given a 30-day option to purchase an additional 15% of the shares. The offering is subject to market conditions and may vary in size and terms. TELA intends to use the proceeds for general corporate purposes, including sales and marketing, research and development, and working capital. The offering will be conducted under a shelf registration statement effective since December 29, 2020. Jefferies, Piper Sandler, and Lake Street are joint book-running managers. This press release does not serve as an offer to sell or a solicitation for purchase of these securities.

TELA Bio, a commercial-stage medical technology company, has announced that its OviTex Reinforced Tissue Matrix will be featured in three case reports at the 2023 SAGES conference in Montreal from March 29 - April 1. These presentations will focus on the use of OviTex in robotic-assisted hernia repair, showcasing its distinctive design that facilitates minimally invasive procedures. The reports include complex cases such as robotic hernia repairs in immunosuppressed patients and the treatment of Spigelian hernias. TELA Bio aims to optimize surgical outcomes while reducing reliance on permanent synthetic materials.

TELA Bio (NASDAQ: TELA) has received 510(k) clearance from the FDA for its OviTex PRS Long-Term Resorbable product, designed to reinforce soft tissue in plastic and reconstructive surgery. This addition complements the existing OviTex PRS portfolio, enhancing its offerings with a fully resorbable polymer and bi-directional stretch. The company aims to optimize clinical outcomes while prioritizing patient anatomy preservation. CEO Antony Koblish emphasizes this product's role in expanding clinical utility and reflecting TELA's commitment to innovation in soft-tissue repair.

TELA Bio, Inc. reported strong financial results for Q4 2022 and full year 2022, achieving revenue of $11.6 million in Q4 and $41.4 million for the full year, marking growth of 39% and 41% respectively year-over-year. The increases were driven by heightened demand for OviTex® and OviTex PRS products, with year-over-year growth of 26% and 92%. Despite operational losses of $10 million for Q4 and $44.3 million for the full year, TELA anticipates revenue growth of 45% to 57% in 2023, projecting revenue between $60 million and $65 million. A new dual-source agreement and product launches further support their optimistic outlook.

TELA Bio (NASDAQ: TELA) announces positive findings from six studies demonstrating the effectiveness of OviTex Reinforced Tissue Matrix in hernia repair and abdominal wall reconstruction. Published in 2022, these studies encompass data from 280 patients, showcasing lower complication and recurrence rates compared to traditional mesh products. The research highlights OviTex as a superior alternative in various applications, aligning with the growing demand for safer surgical options. With over two million hernia repairs expected in the US and Europe this year, TELA aims to enhance patient outcomes through innovative soft-tissue solutions.

TELA Bio, Inc. (NASDAQ: TELA), a company focused on innovative soft-tissue reconstruction solutions, will report its fourth quarter and full year 2022 financial results on March 21, 2023. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide corporate updates. TELA Bio aims to optimize clinical outcomes by prioritizing the preservation of patients' anatomy, providing economically effective solutions while minimizing long-term exposure to synthetic materials. Investors and interested parties can register for the call in advance or access a replay on TELA's website.

TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company, announced the approval of restricted stock units covering 2,600 shares for three newly-hired employees, effective February 21, 2023. This grant was made under the Nasdaq Rule 5635(c)(4) inducement grant exception, as part of the employees' compensation and to encourage their acceptance of employment with TELA Bio. The restricted stock units will vest annually over four years, contingent on the employees' continued service. TELA Bio aims to enhance clinical outcomes through innovative soft-tissue reconstruction solutions, prioritizing the use of the patient's own anatomy.